Canlyniadau Chwilio - Massimo Di Maïo

Mireinio'r Canlyniadau
  1. 1
    Quality of Life in elderly patients with cancer.

    Quality of Life in elderly patients with cancer. gan Massimo Di Maïo, Federica Perrone

    Cyhoeddwyd 2003
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles

    Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles gan Antônio Rossi, Massimo Di Maïo

    Cyhoeddwyd 2016
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    A review of guidelines for lung cancer

    A review of guidelines for lung cancer gan Paolo Bironzo, Massimo Di Maïo

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Association Between Health-Related Quality of Life Measures and Survival Endpoints in Oncology Clinical Trials and in Clinical Decision Making: A Narrative Review

    Association Between Health-Related Quality of Life Measures and Survival Endpoints in Oncology Clinical Trials and in Clinical Decision Making: A Narrative Review gan Anna Amela Valsecchi, Massimo Di Maïo

    Cyhoeddwyd 2025
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Real-World Evidence in Oncology: Opportunities and Limitations

    Real-World Evidence in Oncology: Opportunities and Limitations gan Massimo Di Maïo, Francesco Perrone, Pierfranco Conté

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials

    Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials gan Francesco Facchinetti, Massimo Di Maïo, Marcello Tiseo

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    A meta-analysis of the impact of bronchial stump coverage on the risk of bronchopleural fistula after pneumonectomy

    A meta-analysis of the impact of bronchial stump coverage on the risk of bronchopleural fistula after pneumonectomy gan Massimo Di Maïo, Federica Perrone, Claude Deschamps, Gaetano Rocco

    Cyhoeddwyd 2014
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    COVID-19 Emergency and the Need to Speed Up the Adoption of Electronic Patient-Reported Outcomes in Cancer Clinical Practice

    COVID-19 Emergency and the Need to Speed Up the Adoption of Electronic Patient-Reported Outcomes in Cancer Clinical Practice gan Laura Marandino, Andrea Necchi, Massimo Aglietta, Massimo Di Maïo

    Cyhoeddwyd 2020
    Cael y testun llawn
    Editorial
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Papillary renal cell carcinoma: A review of the current therapeutic landscape

    Papillary renal cell carcinoma: A review of the current therapeutic landscape gan Giulia Courthod, Marcello Tucci, Massimo Di Maïo, Giorgio V. Scagliotti

    Cyhoeddwyd 2015
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis

    Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-... gan Alfredo Addeo, Giuseppe Luigi Banna, Giulio Metro, Massimo Di Maïo

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions

    Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions gan Alessandro Morabito, Ermelinda De Maio, Massimo Di Maïo, Nicola Normanno, Federica Perrone

    Cyhoeddwyd 2006
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer

    Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer gan Consuelo Buttigliero, Marcello Tucci, Francesca Vignani, Giorgio V. Scagliotti, Massimo Di Maïo

    Cyhoeddwyd 2017
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer

    Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer gan Francesca Vignani, Valentina Bertaglia, Consuelo Buttigliero, Marcello Tucci, Giorgio V. Scagliotti, Massimo Di Maïo

    Cyhoeddwyd 2016
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions

    Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions gan Marcello Tucci, Clizia Zichi, Consuelo Buttigliero, Francesca Vignani, Giorgio V. Scagliotti, Massimo Di Maïo

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Tackling ALK in non-small cell lung cancer: the role of novel inhibitors

    Tackling ALK in non-small cell lung cancer: the role of novel inhibitors gan Francesco Facchinetti, Marcello Tiseo, Massimo Di Maïo, Paolo Graziano, Emilio Bria, Giulio Rossi, Silvia Novello

    Cyhoeddwyd 2016
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer

    Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer gan Consuelo Buttigliero, Marcello Tucci, Valentina Bertaglia, Francesca Vignani, Paolo Bironzo, Massimo Di Maïo, Giorgio V. Scagliotti

    Cyhoeddwyd 2015
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    Neuroendocrine breast carcinoma: a rare but challenging entity

    Neuroendocrine breast carcinoma: a rare but challenging entity gan Elena Trevisi, Anna La Salvia, Lorenzo Daniele, Maria Pia Brizzi, Gaetano De Rosa, Giorgio V. Scagliotti, Massimo Di Maïo

    Cyhoeddwyd 2020
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    Is flexible bronchoscopy necessary to confirm the position of double-lumen tubes before thoracic surgery?☆

    Is flexible bronchoscopy necessary to confirm the position of double-lumen tubes before thoracic surgery?☆ gan Mario De Bellis, Rosanna Accardo, Massimo Di Maïo, Carmine Lamanna, Giovanni Battista Rossi, Maria Caterina Pace, Vincenzo Romano, Gaetano Rocco

    Cyhoeddwyd 2011
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer

    Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer gan Massimo Di Maïo, Francesco Perrone, Paolo Chiodini, Ciro Gallo, Carlos Camps, Wolfgang Schuette, Élisabeth Quoix, Chun-Ming Tsai, Cesare Gridelli

    Cyhoeddwyd 2007
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    Implications of KRAS mutations in acquired resistance to treatment in NSCLC

    Implications of KRAS mutations in acquired resistance to treatment in NSCLC gan Marzia Del Re, Eleonora Rofi, Giuliana Restante, Stefania Crucitta, E. Arrigoni, Stefano Fogli, Massimo Di Maïo, Iacopo Petrini, Romano Danesi

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: